Incontinence Drugs: Medications That Cause or Treat Urinary Incontinence

Why Some Medications Cause Incontinence

Certain prescription and over-the-counter drugs disrupt the normal balance between bladder storage and emptying. The bladder relies on coordinated signaling between the detrusor muscle, urethral sphincter, and autonomic nervous system. Drugs that interfere with any part of this circuit can produce leakage, urgency, or retention-overflow.

A 2019 systematic review in the BMJ identified drug-induced urinary incontinence as an underrecognized contributor to new-onset symptoms, particularly in older adults taking five or more medications [1]. The American Geriatrics Society Beers Criteria specifically flags several drug classes as potentially inappropriate in older adults with incontinence [2].

Diuretics increase urine volume rapidly, overwhelming a bladder that may already have reduced capacity. Loop diuretics like furosemide are the most common offenders. Switching to a thiazide or adjusting dosing timing can reduce nighttime episodes by 40-60% in some patients.

Alpha-adrenergic blockers (tamsulosin, doxazosin) relax the bladder neck and proximal urethra. In men taking these drugs for benign prostatic hyperplasia, stress-type leakage may develop. Women prescribed alpha-blockers for hypertension face a similar risk, though this is less commonly recognized.

Cholinesterase inhibitors (donepezil, rivastigmine) increase acetylcholine activity at the detrusor, directly stimulating bladder contractions. A cohort study of 65,997 older adults found that cholinesterase inhibitor use was associated with a 1.55-fold increased risk of urinary incontinence [3].

Sedative-hypnotics and benzodiazepines reduce awareness of bladder fullness and impair the mobility needed to reach a toilet in time. This functional component makes them especially problematic in hospitalized and institutionalized patients.

ACE inhibitors do not act on the bladder directly. Their mechanism involves chronic cough, which raises intra-abdominal pressure repeatedly, worsening or unmasking stress urinary incontinence in women with pelvic floor weakness.

Drugs That Treat Urgency Urinary Incontinence

Antimuscarinics and beta-3 adrenergic agonists are the two pharmacologic pillars for urgency urinary incontinence (UUI) and overactive bladder (OAB). The AUA/SUFU guideline updated in 2019 recommends behavioral therapies as first-line treatment, with medication added when behavioral approaches alone are insufficient [4].

Antimuscarinics block muscarinic (M3) receptors on the detrusor muscle, reducing involuntary contractions. Six agents are FDA-approved: oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, and trospium.

Oxybutynin extended-release (5-30 mg daily) reduces UUI episodes by approximately 71% compared to 36% with placebo, according to pooled trial data [5]. Solifenacin 5 mg demonstrated a mean reduction of 1.5 urgency episodes per day versus 0.9 with placebo in the STAR trial (N=1,281) [6]. Dry mouth affects 20-30% of patients on oral antimuscarinics. Constipation, blurred vision, and cognitive side effects are also reported.

The cognitive safety signal is real. A large nested case-control study published in JAMA Internal Medicine (N=284,343) found that cumulative antimuscarinic exposure over 10 years was associated with a 1.49-fold increase in dementia diagnosis (adjusted OR 1.49 to 95% CI 1.44-1.54) [7]. This finding has shifted prescribing patterns decisively toward beta-3 agonists in older adults.

Mirabegron (Myrbetriq, 25-50 mg daily) activates beta-3 adrenergic receptors on the detrusor, promoting relaxation during filling without blocking muscarinic receptors. The SCORPIO trial (N=1,978) showed mirabegron 50 mg reduced incontinence episodes by 1.57 per day versus 1.17 with placebo [8]. Hypertension (mean systolic increase of 1-2 mmHg) is the primary safety concern.

Vibegron (Gems, 75 mg daily), a newer beta-3 agonist, showed no clinically meaningful blood pressure increase in the EMPOWUR trial (N=1,518), reducing UUI episodes by 1.8 per day versus 1.3 with placebo [9]. This blood pressure neutrality makes vibegron a strong option for patients with concurrent hypertension.

Dr. Roger Dmochowski, professor of urology at Vanderbilt University Medical Center, has stated: "The shift toward beta-3 agonists in older adults is not just about efficacy. It reflects a risk calculus where cognitive preservation takes priority over marginal differences in dry mouth rates."

Pharmacotherapy for Stress Urinary Incontinence

No oral medication is FDA-approved specifically for stress urinary incontinence (SUI) in the United States. This gap means that pharmacologic management of SUI relies on off-label prescribing, and the evidence base is narrower than for UUI.

Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is approved for SUI in Europe and used off-label in the U.S. It increases pudendal nerve activity, strengthening urethral sphincter contraction during the storage phase. A Cochrane review of 7,735 women across multiple trials found duloxetine 80 mg daily reduced incontinence episode frequency by 50% compared to a 33% reduction with placebo [10]. Nausea affected 23% of patients and was the leading cause of discontinuation.

Topical estrogen (vaginal cream, ring, or tablet) can improve urethral mucosal coaptation in postmenopausal women. The Cochrane review on local estrogen for urinary incontinence found that vaginal estrogen reduced incontinence episodes (RR 0.74 to 95% CI 0.64-0.86) compared to placebo, though the quality of evidence was moderate [11]. Systemic oral estrogen, by contrast, worsens incontinence. The Women's Health Initiative found a 53% increased risk of urinary incontinence with conjugated equine estrogen plus medroxyprogesterone [12].

The distinction matters. Topical estrogen helps. Oral systemic estrogen hurts. Patients and clinicians sometimes conflate the two.

Alpha-adrenergic agonists like pseudoephedrine increase urethral tone but carry cardiovascular risks that limit their use. Midodrine has been studied in small trials but is not recommended by any major guideline for SUI.

Pelvic floor muscle training remains the first-line recommendation for SUI per the NICE 2019 guidelines, and a supervised program of at least 3 months should be attempted before or alongside pharmacotherapy [13].

Third-Line and Procedural Options for Refractory Incontinence

When oral medications fail or produce intolerable side effects, three third-line approaches are recommended by the AUA/SUFU guidelines [4].

OnabotulinumtoxinA (Botox) injection into the detrusor muscle (100 units for idiopathic OAB, 200 units for neurogenic detrusor overactivity) produces a median 3.3 fewer UUI episodes per day compared to 1.1 with placebo, based on the ABC trial (N=249) [14]. Effects last 6-9 months. The trade-off is a 5-6% risk of urinary retention requiring intermittent catheterization.

Sacral neuromodulation (InterStim) delivers electrical pulses to the S3 nerve root, modulating bladder reflex pathways. Five-year success rates reach 60-70% in published registries [15]. A newer rechargeable device (InterStim Micro) has reduced the need for battery replacement surgeries.

Percutaneous tibial nerve stimulation (PTNS) involves weekly 30-minute sessions for 12 weeks, followed by monthly maintenance. The SUmiT trial (N=220) demonstrated that 54.5% of PTNS-treated patients achieved moderate or marked improvement versus 20.9% with sham [16].

For stress incontinence refractory to pelvic floor therapy, the midurethral sling remains the gold-standard surgical intervention. Bulking agent injections (e.g., Bulkamid) offer a less invasive alternative with 70% short-term improvement rates, though durability beyond 2 years is variable.

How Prescribers Choose Between Incontinence Medications

Medication selection depends on the incontinence subtype, patient age, comorbidities, and concurrent medications. The decision is not simply "pick any antimuscarinic."

For UUI in adults under 65 without cognitive concerns, antimuscarinics and beta-3 agonists are equally reasonable first choices. Cost often drives the initial pick: generic oxybutynin ER costs $10-30/month versus $300-400/month for branded mirabegron or vibegron before insurance.

For UUI in adults 65 and older, the AGS Beers Criteria and accumulating dementia data argue strongly for beta-3 agonists as first-line. If an antimuscarinic is used, trospium (which does not cross the blood-brain barrier as readily) is the preferred agent in this population.

For mixed incontinence (combined stress and urgency), treating the dominant symptom first is standard practice. If urgency predominates, start a beta-3 agonist. If stress symptoms are more bothersome, prioritize pelvic floor training with or without duloxetine.

Combination therapy using mirabegron 25-50 mg plus solifenacin 5 mg received attention after the BESIDE trial (N=2,174) showed the combination reduced UUI episodes by 1.8 per day versus 1.3 with solifenacin alone and 1.5 with mirabegron alone [17]. The combination was well tolerated, with no increase in post-void residual volumes.

Dr. Phillip Hanno, professor emeritus of urology at the University of Pennsylvania, noted: "Combination therapy with a beta-3 agonist and low-dose antimuscarinic gives us the best efficacy numbers we have ever seen in OAB without the cognitive penalty of high-dose antimuscarinic monotherapy."

Medications to Review if Incontinence Is New or Worsening

A medication review should be the first step when a patient presents with new or worsening incontinence. The mnemonic DIAPPERS (adapted from Resnick's classic formulation) remains a useful framework: Delirium, Infection, Atrophic vaginitis, Pharmaceuticals, Psychological, Excessive urine output, Restricted mobility, Stool impaction [18].

The "Pharmaceuticals" category is where prescribers most frequently find reversible causes. A practical approach involves listing every current medication and screening for these high-risk classes:

• Loop and thiazide diuretics: rapid bladder filling
• Alpha-blockers: reduced urethral tone
• Cholinesterase inhibitors: increased detrusor contractility
• Opioids: retention leading to overflow incontinence
• Gabapentinoids: peripheral edema causing nocturia and overflow
• Lithium: nephrogenic diabetes insipidus producing polyuria
• SGLT2 inhibitors (empagliflozin, dapagliflozin): glucosuria increases urine volume by 200-500 mL/day

SGLT2 inhibitors deserve special attention. Their cardiovascular and renal benefits are well established, but the incontinence side effect is frequently omitted from patient counseling. In the EMPA-REG OUTCOME trial, urinary tract infections and increased urination were reported significantly more often with empagliflozin than placebo [19]. Patients starting an SGLT2 inhibitor should be warned about increased urinary frequency and potential worsening of pre-existing incontinence.

Deprescribing the offending agent or adjusting its dose resolves incontinence in a meaningful percentage of cases. One study of hospitalized older adults found that medication review and modification improved continence in 30% of patients within 48 hours, without any bladder-specific drug being added [20].

Timeline and Expectations for Incontinence Medications

Patients often abandon incontinence medications before they reach peak effect. Setting realistic expectations at the time of prescribing reduces premature discontinuation.

Antimuscarinics and beta-3 agonists typically show initial benefit within 2-4 weeks, but maximum efficacy requires 8-12 weeks of consistent use. The AUA/SUFU guideline recommends a minimum 4-8 week trial before concluding that a medication has failed [4].

OnabotulinumtoxinA produces noticeable improvement within 2 weeks of injection. Peak effect occurs at 4-6 weeks. Repeat injection is typically needed every 6-9 months, though some patients extend to 12 months.

Duloxetine for SUI may take 2-4 weeks to show benefit. The nausea that affects roughly one in four patients typically resolves within the first 1-2 weeks. Starting at 20 mg twice daily for two weeks before escalating to 40 mg twice daily reduces early dropout.

Topical vaginal estrogen requires 4-12 weeks of consistent use before urethral tissue changes translate into symptom improvement. Patients should be counseled that this is a long-term maintenance therapy, not a quick fix.

One-year persistence rates for OAB medications remain low across studies. A large claims-based analysis found that only 12-25% of patients remained on their initial antimuscarinic at 12 months [21]. Beta-3 agonists show modestly better persistence, likely due to fewer bothersome side effects.

The most common reason patients stop is not lack of efficacy. It is side effects (particularly dry mouth with antimuscarinics) and unrealistic expectations about the degree of improvement. A 50-75% reduction in episodes is a successful outcome. Complete dryness from medication alone is uncommon.